{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:30:49Z","timestamp":1780353049596,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bmc.2024.118011","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T18:46:40Z","timestamp":1732128400000},"page":"118011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Discovery of 3-(2-aminobenzo[d]thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition"],"prefix":"10.1016","volume":"117","author":[{"given":"Fang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.118011_b0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.bmc.2024.118011_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020246","article-title":"Advances in non-small cell lung cancer (NSCLC) treatment-A paradigm shift in oncology","volume":"17","author":"Ali","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2024.118011_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2023.8675","article-title":"The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer (Review)","volume":"51","author":"Cheng","year":"2023","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bmc.2024.118011_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1125547","article-title":"Recent progress in targeted therapy for non-small cell lung cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.118011_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05626-2","article-title":"Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC","volume":"9","author":"Arasada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.118011_b0030","first-page":"1","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.118011_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.17","article-title":"MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells","volume":"6","author":"Jakobsen","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bmc.2024.118011_b0040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.21037\/tlcr-24-98","article-title":"MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations","volume":"13","author":"J\u00f8rgensen","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bmc.2024.118011_b0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2024.118011_b0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41401-023-01205-4","article-title":"Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages","volume":"45","author":"Lin","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2024.118011_b0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.21037\/tlcr-24-85","article-title":"Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications","volume":"13","author":"Su","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bmc.2024.118011_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2019.05.016","article-title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer","volume":"458","author":"Liu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2024.118011_b0065","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.118011_b0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cas.12858","article-title":"Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1\/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma","volume":"107","author":"Ida","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2024.118011_b0075","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1021\/acs.jmedchem.4c00175","article-title":"Discovery of novel receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer treatment","volume":"67","author":"Luo","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110402","article-title":"The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer","volume":"121","author":"Meng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2024.118011_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.914838","article-title":"Chondroitin sulfates control invasiveness of the basal-like breast cancer cell line MDA-MB-231 through ROR1","volume":"12","author":"Nadanaka","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2024.118011_b0090","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.bmc.2024.118011_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109420","article-title":"A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo","volume":"119","author":"Yin","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2024.118011_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/srep36447","article-title":"ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.118011_b0105","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis","volume":"73","author":"Cui","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2024.118011_b0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-induced ROR1 Is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2024.118011_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10060","article-title":"ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.118011_b0120","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood.V128.22.2034.2034","article-title":"Cirmtuzumab targets ROR1 to inhibit ibrutinib-resistant, Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia","volume":"128","author":"Yu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.118011_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106484","article-title":"Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1","volume":"135","author":"Fan","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2024.101136","article-title":"Design, synthesis and biological evaluation of sulfonamide derivatives of Benzothiazol-Quinoline-Pyrazoles as anticancer agents","author":"Edukondalu","year":"2024","journal-title":"Chem Data Collect"},{"key":"10.1016\/j.bmc.2024.118011_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139307","article-title":"Exploring the anti-Alzheimer potential: design, synthesis, biological activity, and molecular docking study of benzothiazol-1,3,4-oxadiazole-acetamide compounds","volume":"1318","author":"Hosseini Nasab","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2024.118011_b0140","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1039\/D4RA01874E","article-title":"In the pursuit of novel therapeutic agents: synthesis, anticancer evaluation, and physicochemical insights of novel pyrimidine-based 2-aminobenzothiazole derivatives","volume":"14","author":"Ismail","year":"2024","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2024.118011_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106175","article-title":"Synthesis, characterization, in-silico, and pharmacological evaluation of new 2-amino-6-trifluoromethoxy benzothiazole derivatives","volume":"130","author":"Malik","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104259","article-title":"Targeting EGFR tyrosine kinase: synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives","volume":"104","author":"Mokhtar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113070","article-title":"4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: a promising scaffold towards bioactive molecules","volume":"213","author":"Plescia","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2024.101153","article-title":"Design, synthesis and anticancer evaluation of chalcone functionality bearing benzothiazol-oxazole-pyrazine as anticancer agents","volume":"52","author":"Reddy","year":"2024","journal-title":"Chem Data Collect"},{"key":"10.1016\/j.bmc.2024.118011_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139424","article-title":"Synthesis, electrochemical, biological and catalytical studies of half-sandwich Ru(II)-NSHC complexes bearing benzothiazol-2-ylidene","author":"Tuncer","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2024.118011_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137266","article-title":"Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors","volume":"1300","author":"Jiang","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2024.118011_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115243","article-title":"Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1","volume":"251","author":"Lu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116039","article-title":"Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"264","author":"Xue","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114215","article-title":"Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in vitro and in vivo","volume":"233","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107450","article-title":"Synthesis and antitumor activities of novel 3-(6-aminopyridin-3-yl)benzamide derivatives: inducing cell cycle arrest and apoptosis via AURKB transcription inhibition","volume":"148","author":"Zhao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106352","article-title":"Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A\/PI3K\/BRD4 inhibition","volume":"132","author":"Fan","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2024.118011_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114790","article-title":"Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors","volume":"243","author":"Lu","year":"2022","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:01:05Z","timestamp":1737795665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624004255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"alternative-id":["S0968089624004255"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.118011","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 3-(2-aminobenzo[d]thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.118011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118011"}}